Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/07/2025 BST			5-day change	1st Jan Change
6.040 ^USD	+2.90%		+0.67%	-43.56%

06-06	Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025	RE
05-12	Bolt Biotherapeutics, Inc. - Special Call

Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 12/05/2025 at 21:08

Bolt Biotherapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 11.04 million compared to USD 10.81 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.28 a year ago.

Latest news about Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025	06-06	RE
Bolt Biotherapeutics, Inc. - Special Call	05-12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs Targeting Cea and PD-L1 At AACR Annual Meeting 2025	04-30	CI
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 At AACR Annual Meeting 2025	04-25	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	03-24	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	03-24	CI
Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	03-23	CI
Aadi Bioscience Appoints David Dornan, Phd, as Chief Scientific Officer	02-18	CI
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc	02-11	CI
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024	12-23	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-12	CI
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting	11-07	CI
Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors	04/09/24	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	13/08/24	CI
Bolt Biotherapeutics, Inc. Announces Management Changes	20/05/24	CI
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	20/05/24	CI
Top Midday Decliners	15/05/24	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05/24	MT
Top Premarket Decliners	15/05/24	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15/05/24	MT
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	15/05/24	MT
Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05/24	MT
HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05/24	MT
Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	15/05/24	MT

Chart Bolt Biotherapeutics, Inc.

Duration

Period

BOLT: Dynamic Chart

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-05 - Q2 2025 Earnings Release (Projected)

More about the company